Kerry Expands Ireland Facility for Lactose Free Dairy Growth
Kerry has expanded its biotechnology manufacturing facility in Carrigaline, Ireland, boosting lactase enzyme capacity to meet surging demand for lactose‑free and sugar‑reduced dairy. The upgrade tightly couples advanced enzyme engineering and strain development with large‑scale production, linking the Global Innovation Centre and the Leipzig Biotechnology Centre. The enlarged plant now processes over two million tonnes of milk annually, serving more than 200 customers in 80+ countries and reaching roughly 28 million consumers. Kerry says the investment speeds product development, improves supply reliability, and helps customers launch new dairy products faster.
AlphaGen Therapeutics to Present Preclinical Studies of Two Next-Generation Alpha Therapies at AACR 2026
AlphaGen Therapeutics announced it will present preclinical data on two next‑generation alpha radiopharmaceuticals, AG1002 and AG1206, at the AAC 2026 meeting in San Diego. AG1002 is a non‑agonist SSTR2‑targeting agent that achieved a superior tumor‑to‑kidney ratio and robust tumor inhibition in multiple...
Speed, Scale, and Simplicity in Microarray Analyzer
Thermo Fisher Scientific introduced the SwiftArrayStudio microarray analyzer, a fully automated platform that consolidates hybridization, staining, washing and scanning into a single instrument. The system can deliver genomic results in roughly 30 hours, a dramatic reduction from the traditional five‑day turnaround....
Planetary Nets $28M to Scale Full-Stack Fermentation Platform for Sustainable Proteins
Swiss biotech startup Planetary secured CHF16 million ($20.4 million) in Series A financing and an additional CHF6 million ($7.6 million) credit facility, bringing total capital to roughly $41 million. The funds will expand its BioBlocks full‑stack fermentation platform, scale a global licensing business, and diversify its...
EpiBiologics Reports First Patient Dosed in P-I Study of EPI-326 for EGFR-Driven Solid Tumors
EpiBiologics has dosed the first patient in a global Phase‑1 trial of EPI‑326, a tissue‑selective bispecific antibody that targets EGFR in advanced solid tumors. The study will assess safety, tolerability, pharmacokinetics and early anti‑tumor activity in non‑small cell lung cancer...
ATP Depletion the Key Driver of Ferroptosis in Alzheimer’s Brains
Recent research highlights three distinct breakthroughs: administering cancer immunotherapy earlier in the day can slash patient mortality, a novel fluorescent sensor enables instant detection of E. coli in catheter bags to curb urinary‑tract infections, and digital‑twin models are being used...
3D Printing Is Now Possible Inside Living Cells
Researchers have unveiled a suite of breakthroughs that could reshape bio‑manufacturing and quantum technology. An AI‑driven digital light processing resin now permits 3D printing directly inside living cells, opening pathways for cellular‑level tissue engineering. Parallel studies revealed anomalous reverse heat...
What Are Biologics and Small Molecules for Ulcerative Colitis?
Advanced therapies—biologics and small molecules—offer targeted treatment for moderate to severe ulcerative colitis. Biologics are injectable antibodies that block specific immune proteins, while small molecules are oral agents that inhibit intracellular inflammatory pathways. Clinical experience shows remission often begins within...
Emyria Launches Empax Global Partnership Platform Targeting International Drug Sponsors
Emyria (ASX:EMD) has launched the Empax Global Partnership Platform, giving international drug sponsors and CROs direct access to its clinical delivery infrastructure for complex psychedelic‑assisted therapies. The service creates a dual‑revenue model that blends existing reimbursed treatment programs with high‑margin,...
Pinnacle Food Group Develops Breakthrough Process for Recombinant Breast Milk Protein at Hong Kong Lab
Canadian biotech Pinnacle Food Group announced a methanol‑free precision‑fermentation process that produces recombinant human lactoferrin using a patented Pichia yeast strain at its Hong Kong lab. The new method eliminates toxic methanol, reducing capital and operating expenses while delivering a...
Single-Cell Transcriptomics of Human Brain Disorders
A surge of single‑cell and single‑nucleus transcriptomic studies is redefining the molecular architecture of Alzheimer’s disease and related brain disorders. Researchers have cataloged dozens of cell‑type specific signatures, from microglial states driven by TREM2 variants to endothelial and astrocyte dysregulation....
Nano-X Imaging Ltd (NNOX) Q4 2025 Earnings Call Transcript
Nyxoah (NNOX) reported its first full quarter of U.S. commercialization after the August 2025 FDA approval of its Genio hypoglossal nerve stimulation system. Q4 2025 generated €3.5 million in U.S. net revenue and €5.6 million globally, with a 64% gross margin, while...
HIV Treatment Reduces Accelerated Biological Aging by Nearly Four Years, Landmark Study Shows
A landmark study presented at ESCMID Global 2026 shows that antiretroviral therapy (ART) reduces the accelerated biological aging seen in people with HIV (PWH) by an average of 3.7 years after roughly 1.5 years of treatment. Researchers used a plasma...
Antibiotic Resistance Genes Found in Newborns Within Hours of Birth, Study Shows
A new ESCMID Global 2026 study examined meconium from 105 NICU infants and found antibiotic resistance genes (ARGs) within hours of birth. The most prevalent genes were oqxA (98%) and qnrS (96%), with beta‑lactamase genes such as blaCTX‑M present in...
A Light-Controlled 'Muscle' Could Give Synthetic Cells a New Way to Move
Engineers at Georgia Tech have created a light‑controlled protein network that mimics a muscle, using calcium‑triggered contraction instead of ATP‑driven motors. The system relies on the ciliate protein Tcb2 and a light‑sensitive calcium cage to release calcium on demand, achieving...
Here’s Simulations Plus Inc (SLP)’s Vision for AI in Drug Development
Simulations Plus Inc (NASDAQ:SLP) announced on March 26 that three major pharmaceutical firms have joined its AI‑enabled modeling collaboration programs, embedding the company’s AI agents directly into their drug‑development workflows. The firm emphasized a fully integrated AI deployment rather than...
Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership
Recursion Pharmaceuticals announced an expanded partnership with Citeline on March 31, adding the data‑provider’s real‑world evidence capabilities to its AI‑driven drug discovery platform. The integration is designed to improve clinical‑trial design and accelerate decision‑making for its pipeline of cancer and...
Novel Diabetic Wound Treatment Turns Cells Into Manufacturers
Researchers at Texas A&M have created a novel wound dressing for diabetic foot ulcers that leverages an interwoven extracellular matrix produced by human cells, then strips the cells away, leaving a purely biological scaffold. The approach sidesteps the immune‑rejection and...
StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
Revolution Medicines reported Phase III RASolute 302 results showing its oral RAS inhibitor daraxonrasib extended median overall survival to 13.2 months in previously treated metastatic pancreatic ductal adenocarcinoma, versus 6.7 months for standard chemotherapy (HR 0.40, p < 0.0001). The data sparked a...
Can a Common Parasite Medication Calm the Brain’s Stress Circuitry During Alcohol Withdrawal?
Researchers at UC San Diego discovered that rodents with high P2rx4 gene expression exhibit markedly increased alcohol consumption during withdrawal. Administering the antiparasitic drug ivermectin produced a dose‑dependent reduction in lever‑pressing for alcohol, especially in animals that responded behaviorally. Electrophysiological...
20 Years Of Priority Review Vouchers, A Tool For Spurring Needed Drugs
The U.S. priority review voucher (PRV) program, created in 2007 to spur drug development for neglected tropical diseases (NTDs), has turned into a lucrative market incentive, with vouchers fetching nine‑figure sums. A landmark case is MDGH’s moxidectin, the first new...
STAT+: The Race to Catch KRAS, Pancreatic Cancer’s ‘Greasy Ball,’ and Create the Most Promising Drug in Decades
A new wave of KRAS‑targeted therapies is reshaping pancreatic cancer treatment after decades of failure. Revolution Medicines’ daraxonrasib, a next‑generation KRAS inhibitor, delivered dramatic survival benefits for patient Leanna Stokes, who enrolled in a clinical trial. The drug’s success has...
10x Genomics Unveils Atera Spatial Platform at AACR Meeting
10x Genomics announced the Atera spatial platform at the AACR meeting, promising whole‑transcriptome spatial profiling at scale. The instrument delivers four times the throughput, six times the plex capacity, and up to three‑fold higher sensitivity compared with the company’s Xenium...
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
TG Therapeutics was downgraded from Strong Buy to Buy after a 17% rally that brought its valuation closer to fundamentals. The company’s flagship MS drug, Briumvi IV, continues to capture market share, while a fully enrolled sub‑cutaneous trial could double...
Quality Metrics for Drug Manufacturing
The FDA is advancing a Quality Metrics Reporting Program to collect objective manufacturing data from drug producers. By analyzing these metrics, the agency aims to enhance risk‑based surveillance, predict shortages, and streamline inspections. The initiative builds on a decade of...
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
Definium Therapeutics welcomed the White House’s new executive order that aims to speed research, regulatory review, and access to innovative mental‑health treatments, including psychedelics. The order directs federal agencies to streamline pathways and boost cross‑agency collaboration. Definium highlighted its DT120...
Three Gene Therapy Pioneers Just Won the Breakthrough Prize. This Is Their Story
Three pioneering scientists—Jean Bennett, Albert Maguire, and David J. Wilson—have been honored with the 2026 Breakthrough Prize in Life Sciences for their work on Luxturna, the first gene‑therapy approved by the U.S. Food and Drug Administration. Luxturna treats a rare...
Inocras and Broad Institute Researchers Present New TCGA Whole-Genome Cancer Insights, Accelerating Discovery in Cancer Genomics
Inocras and the Broad Institute will unveil findings from one of the largest whole‑genome cancer analyses ever conducted, covering over 8,000 tumor‑normal pairs from the TCGA across more than 30 cancer types. The joint effort identified more than 250 million variants,...
Wastewater Detects Drug-Resistant Candidozyma Auris Emergence
Researchers published a Nature Communications study showing that wastewater‑based epidemiology can identify drug‑resistant Candida auris in hospitals weeks before patients test positive. By extracting fungal DNA from sewage and applying metagenomic sequencing plus quantitative PCR, the team quantified pathogen load...
They Promise Glowing Skin, a Ripped Body and Better Sex. Peptides Are Having a Moment – but Are They Safe?
Peptide injections have surged in popularity after influencers and startups like Superpower, a $300 million health‑tech firm, began touting benefits ranging from youthful skin to enhanced workouts and sexual performance. The debate intensified when Superpower founder Max Marchione faced off with...
Glycaemic Swings Drive Heart Cell Damage in Diabetes
A new study slated for *Nature Communications* reveals that rapid blood‑sugar swings, not just chronic hyperglycaemia, directly damage heart muscle cells. Researchers showed that glycaemic variability fragments mitochondria, depresses ATP output, disrupts calcium handling and spikes oxidative stress, leading to...
Membrane Protein Amuc_1098 Eases Pancreatitis via TLR2
A study published in Nature Communications identifies the gut bacterium Akkermansia muciniphila membrane protein Amuc_1098 as a potent modulator of Toll‑like receptor 2 (TLR2). By selectively engaging TLR2, Amuc_1098 dampens inflammatory signaling and reshapes pancreatic glycerophospholipid metabolism, leading to marked...
Pliant Therapeutics Announces Presentation of Updated Data From the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid...
Pliant Therapeutics presented updated Phase 1a/1b data for its integrin inhibitor PLN‑101095 combined with pembrolizumab at the 2026 AACR meeting. In ICI‑refractory solid‑tumor patients, the regimen produced an average 89% tumor reduction and a median treatment duration of 19 months among...
Scalable Flow Reactors for Stable Biofilm Formation and Continuous Whole‐Cell Catalysis
Researchers have unveiled a modular, scalable microfluidic reactor that uses flow‑induced deposition to form robust E. coli biofilms directly from suspended cells. By coupling pillar‑based designs with computational fluid dynamics, the team mapped microscale flow features that drive cell attachment,...
Spatially Controlled Capture and Site‐Resolved Analysis of Single Extracellular Vesicles
Researchers have introduced an array‑based platform that captures single extracellular vesicles (EVs) in optically resolvable nanowells and couples it with mask‑gated fluorescence analysis. A PDMS translation step clears excess particles, delivering >99 % capture at predefined locations and low‑background, site‑specific signals....
These Alzheimer’s Drugs Were Supposed to Revolutionize the Way We Fight the Disease. The Reality Is More Complicated.
A new Cochrane Library review casts doubt on the clinical value of Leqimbi and Kisunla, the two Alzheimer’s drugs hailed as breakthroughs in recent years. The analysis of multiple trials finds the medications produce little to no improvement in cognition,...
Lupin Receives Form 483 After USFDA Inspection of Somerset Unit
Lupin Ltd disclosed that the U.S. Food and Drug Administration issued a Form 483 after inspecting its Somerset, New Jersey manufacturing site from April 13‑17, 2026. The FDA cited three observations that may represent violations of the FD&C Act. Lupin said it will address...
5 Most Undervalued Biotech Stocks to Buy Right Now
ADMA Biologics (NASDAQ:ADMA) appears on a list of the five most undervalued biotech stocks, even as Cantor Fitzgerald downgraded the shares to neutral after a short‑seller report alleged channel‑stuffing and rising days‑sales‑outstanding. Cantor highlighted the lack of clear response from...
Brain-on-a-Chip Reveals How Parkinson's Proteins Weaken the Brain's Vascular Barrier
Researchers at Binghamton and Drexel used a microfluidic brain‑on‑a‑chip to study how Parkinson’s‑related alpha‑synuclein aggregates affect the blood‑brain barrier. The study showed that protein clumps cause endothelial dysfunction, barrier disruption, and vascular regression, leading to impaired blood flow. These findings...
Managing Infection Risks in BCMA Bispecific Antibody Therapy: Ajay K. Nooka, MD, MPH
The FDA granted full approval to teclistamab (Tecvayli), a BCMA bispecific antibody for relapsed/refractory multiple myeloma, despite grade 3‑4 infection rates of 50‑60 percent observed in early trials. Ajay K. Nooka, MD, MPH, explained that these infections occurred largely during the COVID‑19 pandemic...
Lilly CEO Sees Weight-Loss Drugs Reaching About Half of Potential Users at Peak
Eli Lilly CEO David Ricks told investors that GLP‑1 weight‑loss drugs will likely reach only about half of the 500 million people worldwide who could benefit, due to institutional and cost barriers. He noted that today roughly one in ten eligible patients...
Pfizer Vaccine Safe, Effective in Juvenile Inflammatory Disease
A multi‑center trial published this week confirms that Pfizer's mRNA COVID‑19 vaccine is both safe and effective for children suffering from juvenile inflammatory diseases such as juvenile idiopathic arthritis and inflammatory bowel disease. The study tracked 312 participants aged 5‑17,...
Trump Expected to Loosen Restrictions on Psychedelic Drugs
President Trump is set to sign an executive order that will loosen federal restrictions on psychedelic drugs such as LSD, ecstasy and psilocybin. The order earmarks $50 million for state‑level ibogaine research, with Texas slated to receive the first grant. It...
How Nanomedicine Gets Inside Your Cells and Treats You From the Inside Out
Nanomedicine is moving from concept to clinic as researchers use lipid‑nanoparticle carriers to deliver synthetic mRNA and siRNA directly into patient cells. The approach lets liver cells produce missing proteins such as factor VIII for hemophilia A, while silencing harmful proteins like...
GLP-1 Receptor Agonists and Risk of Suicide or Suicide Attempts – A Nationwide Cohort and Self-Controlled Case Series Study
A nationwide Danish registry study examined whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) increase suicide or suicide attempts compared with active comparators—SGLT‑2 and DPP‑4 inhibitors. Across two new‑user cohorts totaling over 200,000 GLP‑1 RA initiators, adjusted hazard ratios showed no elevated risk...
Major UKHSA Study Finds Maternal RSV Vaccination Reduces Infant Hospitalization Risk by More Than 80%
Researchers from the UK Health Security Agency presented the largest real‑world evaluation of maternal RSV immunisation, showing that infants whose mothers received the bivalent Prefusion F vaccine at least two weeks before delivery experienced an 81.3% drop in RSV‑related hospitalisations. The...
Pregnancy Vaccine Reduces Baby Hospital Admissions for RSV by 80%
The UK Health Security Agency reports that a maternal RSV vaccine administered from 28 weeks gestation reduces newborn hospital admissions for respiratory syncytial virus by more than 80%. The vaccine offers up to 85% protection when given at least four...
A Robust RP-HPLC Method for Simultaneous Estimation of Paracetamol and Nefopam in Human Plasma: Design of Experiments Approach
A rapid RP‑HPLC method using a Quality by Design framework was validated for simultaneous quantification of paracetamol and nefopam in human plasma. The C18 column with an acetonitrile/0.1 % orthophosphoric acid mobile phase achieved retention times of 6.22 min for paracetamol and...
Viral Immunity and Behavior Sustain Low Mpox Rates
A new Nature Communications study reveals that Los Angeles’ persistent, low‑level mpox incidence is driven by repeated viral introductions and a return to pre‑outbreak sexual behavior patterns. Genomic sequencing traced multiple independent importations rather than a single endemic chain, while mathematical...
New PARP Inhibitor Resistance Mechanisms Found in Ovarian Cancer
A recent British Journal of Cancer study uncovers drug‑specific resistance mechanisms to PARP inhibitors in ovarian cancer, highlighting alterations in PARP trapping, replication‑fork protection, and chromatin‑remodeling. The research shows that resistance is not limited to homologous recombination restoration but involves...